Jacobson Center for Clinical & Translational Research

Main Menu


Additional Information


Contact Us

Brain Cancer Trials

Study Title:  M13-813:  A Randomized, Placebo Controlled Phase 2b/3 Study of ABT-414 with Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects with Newly Diagnosed Glioblastoma (GBM) with Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1) (NCT02573324)

Principal Investigator: Krishna Reddy, M.D.

Purpose:  This study seeks to determine whether the addition of ABT-414 to concomitant radiotherapy and temozolomide (TMZ) prolongs progression free survival (PFS) and overall survival (OS) in participants with newly diagnosed glioblastoma (GBM) with epidermal growth factor receptor (EGFR) amplification.  In addition, this is a Phase 1, open-label, multicenter sub-study to assess the pharmacokinetics, safety and tolerability of ABT-414 in subjects with newly diagnosed EGFR-amplified GBM who have mild or moderate hepatic impairment.

Study Coordinator: For more information email Stephanie Smiddy, RN for call 419.383.6962.


Last Updated: 9/11/17